Clinical Trials
5 trialsNCT02314156 2023-02-22
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Northwestern University
Phase 2 Completed
NCT02323646 2019-06-25
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958334 2019-06-18
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Repros Therapeutics Inc.
Phase 2 Completed
NCT01451424 2014-08-29
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed